Similar articles for PMID: 19884296

Year	Number of Results
1998	1
2000	2
2001	1
2002	4
2003	4
2004	6
2005	12
2006	8
2007	5
2008	22
2009	36
2010	31
2011	26
2012	14
2013	14
2014	8
2015	9
2016	10
2017	9
2018	7
2019	2
2020	3
2021	4
2022	5

1

Dual antiplatelet therapy in coronary artery disease: a case-based approach.

Raymond C, Menon V. Raymond C, et al. Cleve Clin J Med. 2009 Nov;76(11):663-70. doi: 10.3949/ccjm.76a.09045. Cleve Clin J Med. 2009. PMID: 19884296 Free article. Review.

2

Percutaneous coronary intervention: assessing coronary vascular risk associated with bare-metal and drug-eluting stents.

Spinler SA. Spinler SA. Am J Manag Care. 2009 Mar;15(2 Suppl):S42-7. Am J Manag Care. 2009. PMID: 19355808 Free article. Review.

3

Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolysis In Myocardial Infarction) analysis.

Antman EM, Wiviott SD, Murphy SA, Voitk J, Hasin Y, Widimsky P, Chandna H, Macias W, McCabe CH, Braunwald E. Antman EM, et al. J Am Coll Cardiol. 2008 May 27;51(21):2028-33. doi: 10.1016/j.jacc.2008.04.002. J Am Coll Cardiol. 2008. PMID: 18498956 Free article. Clinical Trial.

4

Prasugrel: new drug. After angioplasty and stenting: continue to use aspirin + clopidogrel.

[No authors listed] [No authors listed] Prescrire Int. 2009 Oct;18(103):193-5. Prescrire Int. 2009. PMID: 19877380

5

Indications for dual antiplatelet therapy with aspirin and clopidogrel: evidence-based recommendations for use.

Reaume KT, Regal RE, Dorsch MP. Reaume KT, et al. Ann Pharmacother. 2008 Apr;42(4):550-7. doi: 10.1345/aph.1K433. Epub 2008 Mar 4. Ann Pharmacother. 2008. PMID: 18319394 Review.

6

Antiplatelet therapy in percutaneous coronary intervention: integration of prasugrel into clinical practice.

Thomas D, Giugliano RP. Thomas D, et al. Crit Pathw Cardiol. 2009 Mar;8(1):12-9. doi: 10.1097/HPC.0b013e318196bb46. Crit Pathw Cardiol. 2009. PMID: 19258833 Review.

7

Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38).

Wiviott SD, Antman EM, Gibson CM, Montalescot G, Riesmeyer J, Weerakkody G, Winters KJ, Warmke JW, McCabe CH, Braunwald E; TRITON-TIMI 38 Investigators. Wiviott SD, et al. Am Heart J. 2006 Oct;152(4):627-35. doi: 10.1016/j.ahj.2006.04.012. Am Heart J. 2006. PMID: 16996826 Clinical Trial.

8

Effect of prasugrel versus clopidogrel on outcomes among patients with acute coronary syndrome undergoing percutaneous coronary intervention without stent implantation: a TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet inhibitioN with prasugrel (TRITON)-Thrombolysis in Myocardial Infarction (TIMI) 38 substudy.

Pride YB, Wiviott SD, Buros JL, Zorkun C, Tariq MU, Antman EM, Braunwald E, Gibson CM; TIMI Study Group. Pride YB, et al. Am Heart J. 2009 Sep;158(3):e21-6. doi: 10.1016/j.ahj.2009.06.021. Am Heart J. 2009. PMID: 19699846 Clinical Trial.

9

Efficacy and safety of prasugrel compared with clopidogrel in patients with acute coronary syndromes: results of TRITON-TIMI 38 trials.

Mariani M, Mariani G, De Servi S. Mariani M, et al. Expert Rev Cardiovasc Ther. 2009 Jan;7(1):17-23. doi: 10.1586/14779072.7.1.17. Expert Rev Cardiovasc Ther. 2009. PMID: 19105763

10

Role of antiplatelet therapy across the spectrum of patients with coronary artery disease.

Bhatt DL. Bhatt DL. Am J Cardiol. 2009 Feb 2;103(3 Suppl):11A-19A. doi: 10.1016/j.amjcard.2008.11.018. Am J Cardiol. 2009. PMID: 19166708 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed